-
Russia hits Ukraine power plants despite Trump energy ceasefire claim
-
'Dizzy' Lazio join Inter at top of Serie A as Roma and AC Milan held
-
Isco's Betis rise back above Real Madrid to third
-
Man City must make 'own noise' amid financial scandal, says Maresca
-
Haaland vows troubled Man City will 'stick together' after beating Liverpool
-
Jaguars down Eagles with wild field goal finish in London
-
Abhishek, Arshdeep guide India to T20 win over West Indies
-
Sadaqat, Imran help Pakistan thump Sri Lanka to seal T20 series
-
'Other Mommy' scares up N. American box office win
-
Man City shrug off uncertain future to beat 10-man Liverpool
-
Zelensky surprised, Moscow mum as Trump announces energy ceasefire
-
Conservation groups alarmed at marine mammals' deaths in Spain
-
Ready Player 1: Paris to host 2027 edition of EVO combat video games event
-
Tens of thousands urge climate action at Brussels demo
-
Bill Gates warns cyberattacks most imminent AI threat
-
Norway's Hagenes wins historic Paris-Tours classic
-
Lazio join Inter at top of Serie A as Roma held at Como
-
Kipruto claims Chicago Marathon as Feysa defends women's title
-
Trump says Russia and Ukraine agree to 'energy ceasefire'
-
Forest boss Glasner loses on return to Palace, Hull hold Everton
-
Man City branded 'cheats' in hostile Liverpool reception after guilty verdict
-
'Sorry boys': Hamilton takes blame for botched tyre call
-
Smith breaks fielding record as Australia take control of 1st Test
-
Resurgent Verstappen wins Singapore Grand Prix for first time
-
Smith breaks fielding record as Australia take first innings lead
-
Verstappen wins Singapore Grand Prix for first time
-
Saints win south coast derby after Eckert's suspended 'Spygate' ban
-
Djibouti boat wreck leaves 139 migrants dead, 84 missing: UN
-
Zheng beats Andreeva to become first home player to win China Open
-
Drone hits Russia's Yandex in third reported attack
-
Young pretender Seixas threatens to rule cycling after sensational year
-
Shelton dumped out in Shanghai but Zverev ploughs on
-
Serie A stalemate as Roma held by Como
-
Top seed Zverev digs deep to reach Shanghai last 16
-
Prince Harry, Meghan to carry out first joint engagement since UK return: reports
-
Pope to be operated on for lump on lung
-
Last Ceuta migrant camp removed ahead of Spanish king's visit
-
India's 'cockroach' leaders vow to keep up election protests
-
Ukraine to stop refinery strikes when Russia curbs energy attacks: Zelensky
-
Pope says to be operated in 'coming days' for lung nodule
-
Pakistan imposes emergency rule in Imran Khan's provincial stronghold
-
Ukraine irrelevant to Russia and IOC's relationship: Russian minister
-
Manchester City brace for hostile Liverpool reception after guilty verdict
-
Brennan keeps his cool in Japan for third PGA Tour victory
-
Brazil's Lula accuses Meta of election interference
-
Bezzecchi wins in Indonesia as Martin retakes MotoGP championship lead
-
South Korea completes trial of Arctic shipping route
-
US Open finalist Shelton dumped out in Shanghai third round
-
アレックス・ボディ、CRIFとともに透明性の高い投資と徹底した資金洗浄防止に注力
-
India releases 'cockroach' leaders as movement calls for more protests
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
P.A.Mendoza--AT